<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2071-8713-3865</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-3865</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Алгоритм лечения сахарного диабета 2 типа в свете «гравицентрической концепции»</article-title><trans-title-group xml:lang="en"><trans-title>The gravicentric Concept in type 2 Diabetes: practical implementation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Levit</surname><given-names>Sh</given-names></name></name-alternatives><bio xml:lang="ru"><p>глава Института диабета и эндокринологии, Медицинский центр Ассута, Тель-Авив, Израиль.</p></bio><email xlink:type="simple">shlevit@gmail.com</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Dzeranova</surname><given-names>L K</given-names></name></name-alternatives><bio xml:lang="ru"><p>главный научный сотрудник отделения нейроэндокринологии и остеопатий Института клинической эндокринологии, ФГБУ Эндокринологический научный центр Минздрава РФ</p></bio><email xlink:type="simple">dzeranovalk@yandex.ru</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Philippov</surname><given-names>Yu I</given-names></name></name-alternatives><bio xml:lang="ru"><p>Научный сотрудник отделения программного обучения и лечения Института диабета, ФГБУ Эндокринологический научный центр Минздрава РФ</p></bio><email xlink:type="simple">yuriyivanovich@gmail.ru</email></contrib></contrib-group><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>30</day><month>10</month><year>2013</year></pub-date><volume>10</volume><issue>3</issue><issue-title>№3 (2013)</issue-title><fpage>50</fpage><lpage>54</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Levit S., Dzeranova L.K., Philippov Y.I., 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="ru">Levit S., Dzeranova L.K., Philippov Y.I.</copyright-holder><copyright-holder xml:lang="en">Levit S., Dzeranova L.K., Philippov Y.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/3865">https://www.omet-endojournals.ru/jour/article/view/3865</self-uri><abstract><p>Эпидемический рост числа больных сахарным диабетом 2 типа (СД2) во всем мире продолжается, несмотря на все усилия, предпринимаемые международным врачебным сообществом. Появление новых лекарственных средств не способствует сдерживанию заболеваемости, ужесточение критериев диагностики обусловливает скачкообразный прирост численности больных, а пересмотр основных целей лечения (снижение целевых показателей гликемического контроля) часто становится аргументом в пользу излишне агрессивного подхода к фармакотерапии диабета. Используемые в мире алгоритмы ведения пациентов с СД2 [<xref ref-type="bibr" rid="cit1">1</xref>] основной терапевтической целью ставят достижение и длительное поддержание показателей гликемического контроля, максимально близких к нормальным значениям, при этом практически не акцентируются на устранении факторов, патогенетически связанных с развитием и прогрессированием основного заболевания, таких как гиподинамия и избыток массы тела. Во имя достижения целевых показателей гликемии пациенты нередко получают лечение, которое заведомо способствует набору массы тела, прогрессированию инсулинорезистентности и усилению относительного дефицита инсулина, приводящему в итоге к потребности в экзогенном инсулине. В то же время, активное воздействие на патогенетические факторы развития СД2 – избыток массы тела и гиподинамию – может приводить к восстановлению регуляции углеводного обмена, снижая потребность в фармакотерапии вплоть до полной ее отмены, что было показано во многих крупных исследованиях [<xref ref-type="bibr" rid="cit2">2</xref>]. «Гравицентрическая концепция» лечения СД2 призвана пересмотреть основные терапевтические цели и изменить расстановку акцентов в схеме ведения пациентов. Ее задача состоит и в том, чтобы создать у врачей и пациентов ясное представление о возможности деинтенсификации фармакотерапии при определенных условиях и сфокусировать максимум усилий на устранении факторов прогрессирования заболевания с надеждой на излечение или ремиссию.</p></abstract><trans-abstract xml:lang="en"><p>The epidemic rise of patients with type 2 diabetes mellitus (T2DM) worldwide continues, despite all efforts taken by the international medical community to curb it. It seems that the advent of new drugs does not contribute to a better control of the disease, the tightening up of diagnostic criteria causes an abrupt increase in the number of patients, while a revision of the main goals of treatment (a reduction of targets for glycemic control) often becomes an argument in favor of an overly aggressive approach to drug therapy in diabetes. The main therapeutic goal of existing algorithms for the management of T2DM patients is to achieve and maintain long-term indicators of glycemic control, as close to normal values as possible. However, almost none of these algorithms address the factors associated with the pathogenesis of development and progression of the underlying disease, such as lack of exercise and excessive adiposity. For the sake of achieving glycemic target values, patients often receive treatment that is known to be conducive to weight gain, insulin resistance and increased progression of relative insulin deficiency, eventually leading to the prescription of exogenous insulin. At the same time, an active modification of the pathogenetic factors of T2DM – excess body weight and physical inactivity – may lead to restoration of glucose tolerance, reducing the need of pharmacotherapy until its complete withdrawal, as has been shown in many major studies [<xref ref-type="bibr" rid="cit2">2</xref>]. The "gravicentric concept" of treatment of T2DM is designed to redefine the basic therapeutic targets and change the emphasis in the of patients' management scheme. Its mission is to create a clear idea for both doctors and patients about the possibility of de-intensification of pharmacotherapy under certain conditions, and to focus maximum effort to address the factors of progression of the disease with the hope of a cure or remission</p></trans-abstract><kwd-group xml:lang="en"><kwd>type 2 diabetes</kwd><kwd>body weight</kwd><kwd>algorithm</kwd><kwd>therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE comprehensive diabetes management algorithm 2013. Endocrine Practice. 2013 Mar-Apr;19(2):327-336.</mixed-citation><mixed-citation xml:lang="en">Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE comprehensive diabetes management algorithm 2013. Endocrine Practice. 2013 Mar-Apr;19(2):327-336.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012 Dec 19;308(23):2489-2496. DOI: http://dx.doi.org/10.1001/jama.2012.67929</mixed-citation><mixed-citation xml:lang="en">Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012 Dec 19;308(23):2489-2496. DOI: http://dx.doi.org/10.1001/jama.2012.67929</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Eckel RH, Committee FtN. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997 November 4, 1997;96(9):3248-3250. DOI: http://dx.doi.org/10.1161/01.cir.96.9.3248</mixed-citation><mixed-citation xml:lang="en">Eckel RH, Committee FtN. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997 November 4, 1997;96(9):3248-3250. DOI: http://dx.doi.org/10.1161/01.cir.96.9.3248</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006 Feb 14;113(6):898-918. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.106.171016</mixed-citation><mixed-citation xml:lang="en">Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006 Feb 14;113(6):898-918. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.106.171016</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Frellick M. AMA Declares Obesity a Disease: Medscape; 2013 [09.09.2013]. Available from: http://www.medscape.com/viewarticle/806566</mixed-citation><mixed-citation xml:lang="en">Frellick M. AMA Declares Obesity a Disease: Medscape; 2013 [09.09.2013]. Available from: http://www.medscape.com/viewarticle/806566</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Levit S, Philippov YI, Gorelyshev AS. Type 2 Diabetes Mellitus: time to change the concept. Diabetes Mellitus. 2013 (1):91-102.</mixed-citation><mixed-citation xml:lang="en">Levit S, Philippov YI, Gorelyshev AS. Type 2 Diabetes Mellitus: time to change the concept. Diabetes Mellitus. 2013 (1):91-102.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006 Aug;49(8):1711-1721. DOI: http://dx.doi.org/10.1007/s00125-006-0316-2</mixed-citation><mixed-citation xml:lang="en">Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006 Aug;49(8):1711-1721. DOI: http://dx.doi.org/10.1007/s00125-006-0316-2</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. International Journal of Clinical Practice. 2011 Feb;65(2):165-171. DOI: http://dx.doi.org/10.1111/j.1742-1241.2010.02513.x</mixed-citation><mixed-citation xml:lang="en">Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. International Journal of Clinical Practice. 2011 Feb;65(2):165-171. DOI: http://dx.doi.org/10.1111/j.1742-1241.2010.02513.x</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment. Diabetes Care. 1997 September 1, 1997;20(9):1353-1356. DOI: http://dx.doi.org/10.2337/diacare.20.9.1353</mixed-citation><mixed-citation xml:lang="en">Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment. Diabetes Care. 1997 September 1, 1997;20(9):1353-1356. DOI: http://dx.doi.org/10.2337/diacare.20.9.1353</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">El-Mir M-Y, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I. Journal of Biological Chemistry. 2000 January 7, 2000;275(1):223-228. DOI: http://dx.doi.org/10.1074/jbc.275.1.223</mixed-citation><mixed-citation xml:lang="en">El-Mir M-Y, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I. Journal of Biological Chemistry. 2000 January 7, 2000;275(1):223-228. DOI: http://dx.doi.org/10.1074/jbc.275.1.223</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochemical Journal. 2000 Jun 15, 2000;348(3):607-614. DOI: http://dx.doi.org/10.1042/0264-6021:3480607</mixed-citation><mixed-citation xml:lang="en">Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochemical Journal. 2000 Jun 15, 2000;348(3):607-614. DOI: http://dx.doi.org/10.1042/0264-6021:3480607</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. Journal of Clinical Investigation. 2010 Jul;120(7):2355-2369. DOI: http://dx.doi.org/10.1172/JCI40671</mixed-citation><mixed-citation xml:lang="en">Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. Journal of Clinical Investigation. 2010 Jul;120(7):2355-2369. DOI: http://dx.doi.org/10.1172/JCI40671</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
